Byron Jones
Cardiovascular Disease · Birmingham, ALNPI 1245234137
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novartis at 32.4% of the total. Reporting peaked in 2021 at $871 and has fallen 98.3% since, to $15 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in AL, where the typical reported total is $2,733.
Across 197 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$968
- Johnson & Johnson$295
- Amgen$221
- Sanofi-aventis U.S. LLC$184
- Pfizer$164
- Esperion Therapeutics, Inc.$151
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,89097%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 81 | $968 |
| Johnson & Johnson | 22 | $295 |
| Amgen | 16 | $221 |
| Sanofi-aventis U.S. LLC | 11 | $184 |
| Pfizer | 11 | $164 |
| Esperion Therapeutics, Inc. | 7 | $151 |
| Cvrx, Inc. | 1 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $135 |
| Astellas Pharma US Inc | 2 | $114 |
| Alnylam Pharmaceuticals Inc. | 5 | $94 |
| Boehringer Ingelheim | 5 | $87 |
| Amarin Pharma, Inc. | 4 | $56 |
| Boston Scientific | 3 | $48 |
| Abbott | 3 | $48 |
| Lundbeck LLC | 2 | $47 |
| Irhythm Technologies, Inc. | 3 | $46 |
| Impulse Dynamics (USA) Inc. | 3 | $40 |
| AstraZeneca | 3 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| CSL Behring | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Gilead | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,989 in reported general payments places this provider in the 50th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.